Goldman recommends buying Allergan (AGN +0.2%) on its recent pullback, saying the company is...

|About: Allergan plc (AGN)|By:, SA News Editor

Goldman recommends buying Allergan (AGN +0.2%) on its recent pullback, saying the company is well positioned with its diversified portfolio, emerging market exposure, and high growth potential. The firm reiterates its Buy rating with a $106 price target.